for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Proteostasis Therapeutics Inc

PTI.OQ

Latest Trade

0.97USD

Change

0.02(+1.85%)

Volume

114,559

Today's Range

0.94

 - 

1.00

52 Week Range

0.61

 - 

10.38

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.96
Open
0.96
Volume
114,559
3M AVG Volume
11.17
Today's High
1.00
Today's Low
0.94
52 Week High
10.38
52 Week Low
0.61
Shares Out (MIL)
51.13
Market Cap (MIL)
48.23
Forward P/E
-0.64
Dividend (Yield %)
--

Next Event

Proteostasis Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Proteostasis Therapeutics Says Qtrly Loss Per Share $0.39

Proteostasis Therapeutics Announces Management Changes And Appointments

Proteostasis Says Entered Into Sales Agreement With H.C. Wainwright

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Proteostasis Therapeutics Inc

Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of novel therapeutics to treat cystic fibrosis (CF), and other diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. The Company focuses on identifying therapies that restore protein function. The Company’s CF focused pipeline consists of novel CFTR modulators including correctors, potentiators and amplifiers. The Company’s clinical developments include PTI-801, a third generation CFTR corrector, PTI-808, a CFTR potentiator, and PTI-428, a CFTR amplifier.

Industry

Biotechnology & Drugs

Contact Info

80 Guest St Fl 5

+1.617.2250096

http://www.proteostasis.com/

Executive Leadership

M. James Barrett

Independent Chairman of the Board

Meenu Chhabra

President, Chief Executive Officer, Director

Eric Larson

Principal Financial Officer and Principal Accounting Officer

Marija Zecevic

Chief Operating Officer

Sheila Wilson

Senior Vice President and Director of Clinical Development Operation

Key Stats

2.00 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-2.060

2017

-2.340

2018

-1.610

2019(E)

-1.503
Price To Earnings (TTM)
--
Price To Sales (TTM)
7.97
Price To Book (MRQ)
0.59
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-84.72
Return on Equity (TTM)
-75.33

Latest News

BRIEF-Proteostasis Therapeutics Says CFO Helen Boudreau Provided Notice Of Resignation

* PROTEOSTASIS THERAPEUTICS SAYS ON MAY 2, CFO AND TREASURER, HELEN BOUDREAU, PROVIDED NOTICE OF RESIGNATION TO PURSUE ANOTHER PROFESSIONAL OPPORTUNITY

BRIEF-Proteostasis Therapeutics Files For Mixed Shelf Of Up To $100 Mln

* PROTEOSTASIS THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $100 MILLION - SEC FILING Source text: [https://bit.ly/2H14NPj] Further company coverage:

BRIEF-Proteostasis Receives FDA Fast Track Designation For Triple Combination Program In Patients With Cystic Fibrosis

* PROTEOSTASIS THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR TRIPLE COMBINATION PROGRAM IN PATIENTS WITH CYSTIC FIBROSIS

BRIEF-Proteostasis Announces Proposed Public Offering Of Common Stock

* PROTEOSTASIS THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Proteostasis Therapeutics Expects Cash, Cash Equivalents,Short-Term Investments To Be Enough To Fund Its Operating Expenses

* PROTEOSTASIS THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Proteostasis Therapeutics Sees Cash, Cash Equivalents Balance As Of Dec 31, Sufficient To Fund Operations Into Early 2019​

* PROTEOSTASIS THERAPEUTICS INC - CO ESTIMATES CASH, CASH EQUIVALENTS BALANCE AS OF DEC 31, 2017, SUFFICIENT TO FUND OPERATIONS INTO EARLY 2019 Source text: (http://bit.ly/2FWFOfk) Further company coverage:

BRIEF-Proteostasis Therapeutics Prices Public Offering Of 8 Mln Shares At $5/Share

* PROTEOSTASIS THERAPEUTICS PRICES PUBLIC OFFERING OF COMMON STOCK

BRIEF-Proteostasis Therapeutics Announces Positive Clinical Results From Cystic FibrosisStudies

* PROTEOSTASIS THERAPEUTICS ANNOUNCES POSITIVE CLINICAL RESULTS FROM STUDIES OF PTI-428, PTI-801 AND PTI-808 IN HEALTHY VOLUNTEERS AND PATIENTS WITH CYSTIC FIBROSIS

BRIEF-Proteostasis Therapeutics Q3 loss per share $0.56

* Proteostasis Therapeutics reports third quarter 2017 results and provides CF portfolio update

BRIEF-Proteostasis Therapeutics to prioritize resources on cystic fibrosis R&D

* Proteostasis Therapeutics - initiated strategic prioritization to focus resources on research & development of cystic fibrosis programs, among others

BRIEF-Proteostasis Therapeutics appoints Helen Boudreau as CFO

* Proteostasis appoints Helen Boudreau as chief financial officer

BRIEF-Proteostasis provides update on PTI-428 amplifier clinical data

* PTI-428 amplifier clinical data in three separate populations of CF patients on track for mid-year

BRIEF-Proteostasis diluted EPS $0.54

* Qtrly net loss per share attributable to common stockholders-basic and diluted $0.54

BRIEF-Proteostasis Therapeutics announces conference call at 30th annual North American Cystic Fibrosis Conference

* Proteostasis Therapeutics announces conference call to provide clinical and scientific update at 30th annual North American Cystic Fibrosis Conference Source text for Eikon: Further company coverage: ;))

BRIEF-Proteostasis Therapeutics prices common stock offering

* Proteostasis therapeutics announces pricing of public offering of common stock

BRIEF-Proteostasis Therapeutics files to say it is offering 4.3 mln shares of its common stock

* Files to say it is offering 4.3 million shares of its common stock Source text: [http://bit.ly/2c9dh7j] Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up